DaVita Clinical Research Celebrates Milestone Year
28 December 2012 - 1:00AM
Business Wire
DaVita Clinical Research® (DCR®), a provider of clinical
research services focused on kidney research as well as a multitude
of specialty therapeutic populations, today released a recap of its
milestone year in 2012.
“DaVita Clinical Research experienced a very strong year in
2012,” said Dr. Mahesh Krishnan, vice president of DaVita Clinical
Research. “From expanding our research capabilities to producing
innovative studies with results to drive better clinical outcomes,
we’re making strides to improve the quality of life for chronic
kidney disease and end-stage renal disease patients around the
world.”
Major initiatives and highlights for DCR in 2012
include:
New research facility opened in Colorado – The new
facility encompasses 35,000 square feet and is physically connected
to St. Anthony Hospital in Lakewood, Colo. The 80-bed facility
brought more than 50 specialized research jobs to the area and
increased DCR’s physical capacity from 42 to 122 beds in North
America, including the existing facility in Minnesota. The facility
supports high-risk studies and has expanded ability to support both
patient and healthy volunteer Phase I clinical studies.
DCR hired four key individuals to ignite the expansion at its
latest clinical research facility. The new team members are Dr.
Christopher Galloway, medical director; Chad Jaeger, vice president
of Clinical Operations; Amy Denvir, director of Operations -
Denver; and Michael Kreuter, director of Data Management.
Through this investment, DCR will continue to explore
opportunities to both expand its patient-driven leadership position
and diversify its ability to conduct critical research in healthy
normal volunteers.
Innovative clinical research programs highlighted at
industry meetings – Researchers from DCR and DaVita®, the
dialysis division of DaVita HealthCare Partners Inc., presented
results from a number of innovative clinical improvement programs
and health economic studies originating from DaVita and its
research partners. The findings were shared at three premier health
care meetings in 2012: The National Kidney Foundation Spring
Clinical Meeting, the 17th Annual International Society for
Pharmacoeconomics and Outcomes Research International Meeting, and
the American Society of Nephrology’s Kidney Week.
DCR provides a collaborative bridge between DaVita services and
the pharmaceutical and biotech research community; DCR also shares
DaVita’s dedication to improving the health and well-being of
kidney patients.
2012 abstract highlights include the following:
- Video Education Increases Patient
Knowledge about Phosphorus Control and is a Preferred Form of
Education (Duane Dunn, et al.)
- Improvement in Peritonitis Rates with
the Use of Sodium Hypochlorite (Dr. John Moran, et al.)
- Disease Management Program Reduces
Overall Medical Costs in End-Stage Renal Disease Patients (Dr.
Allen R. Nissenson, et al.)
- Results of a One-Year Assessment of
Quality Indicators in an Acute Dialysis Program Operated by a Large
Dialysis Provide (Dr. Robert Provenzano, et al.)
- Crit-Line Monitor Use in Incident
Hemodialysis Patients Improves Dry Weight and Adequacy, While
Reducing Epoetin Alfa Dose: A Propensity Score Matched Study (Scott
Sibbel, PhD et al.)
- Extracellular Volume Control in
Dialysis Patients To Reduce Hospitalizations (joint study between
DaVita, Fresenius Medical Care, and Renal Ventures, LLL; presented
by Thomas Parker, M.D., Renal Ventures Management, LLC)
- Analysis of the 2014 Quality
Improvement Program Reporting Measures for Calcium Phosphate in
Dialysis Patients (Nissenson, et al.)
- Changing Hemoglobin Targets: Effects on
Epoetin Alfa, Intravenous Iron, and Iron Storage Measures From
2009–2012 (Bond, et al.)
- A Comparative Analysis of Transfusion
Trends between Types of Providers of Dialysis Services Using
Medicare Claims Data (Krishnan, et al.)
- Pseudo-Randomization in Retrospective
Analysis Using the Generalized Multinomial Logit for Propensity
Score Generation
- Odds of Missed Hemodialysis Sessions
are Increased During Holiday Periods Among In-Center Hemodialysis
Patients
- A Managed Care Cost-Offset Model for
Ferric Citrate, an Experimental Phosphate Binder that Can Reduce
the Use of Erythropoiesis-Stimulating Agents (ESA) and Intravenous
Iron in Hemodialysis Patients with Hyperphosphatemia
Enhanced social media presence – In 2012 DCR re-launched
its Facebook page with a new design and focus on clinical research
education as well as announcing upcoming studies. DCR also joined
the Twitter community as @DCRDenver in 2012, with a focus on its
Denver facility and educating potential participants about the
clinical trial process. Dr. Galloway also joined Twitter as
@ChrisGallowayMD this year; his account launched in November and
offers insight to clinical trials as well as general health care
news. Dr. Krishnan continues to share a monthly list of his top
clinical reads through a DaVita blog, featuring thought-provoking
articles from clinical journals and publications as well as
respected nephrology blogs.
DaVita, DaVita Clinical Research, DCR and DaVita HealthCare
Partners are trademarks or registered trademarks of DaVita
Healthcare Partners Inc. All other trademarks are the property of
their respective owners.
About DaVita
DaVita is the dialysis division of DaVita HealthCare Partners
Inc., a Fortune 500® company that, through its operating divisions,
provides a variety of health care services to patient populations
throughout the United States and abroad. A leading provider of
kidney care in the United States, DaVita delivers dialysis services
to patients with chronic kidney failure and end stage renal
disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment
plans, personalized care teams and convenient health-management
services. As of September 30, 2012, DaVita operated or provided
administrative services at 1,912 outpatient dialysis centers
located in the United States serving approximately 150,000
patients. The company also operated 24 outpatient dialysis centers
located in five countries outside the United States. DaVita
supports numerous programs dedicated to creating positive,
sustainable change in communities around the world. The company’s
leadership development initiatives and social responsibility
efforts have been recognized by Fortune, Modern Healthcare,
Newsweek and WorldBlu. For more information, please visit
DaVita.com.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR), a wholly owned subsidiary of
DaVita Healthcare Partners, Inc., is committed to advancing the
knowledge and practice of kidney care. DCR brings knowledge, skill
and expertise to pharmaceutical research, facilitating the success
of its clients’ clinical trials. DCR’s clinical expertise spans the
lifecycle of drug development. DCR’s biorepository, Early Clinical
Research unit (Phase I-IIa) and Clinical Development network of
physicians and investigative sites, data research, Health Economics
& Outcomes Research, Central Laboratory, Advisory Committee
prep, and Medical Communications are focused on providing
world-class clinical research in both complex/specialty populations
and therapeutic areas, and especially in CKD and ESRD populations.
To learn more about DCR, visit www.davitaclinicalresearch.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jul 2023 to Jul 2024